Sanofi-Aventis S.A. ADR (SNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 15,567,040 | 12,255,120 | 12,070,810 | 13,137,840 | 13,820,500 |
| Cost of Goods | 4,491,866 | 3,672,229 | 3,733,722 | 4,358,652 | 4,180,544 |
| Gross Profit | 11,075,170 | 8,582,893 | 8,337,090 | 8,779,189 | 9,639,959 |
| Operating Expenses | 6,872,270 | 7,154,080 | 6,804,800 | 7,403,840 | 6,138,030 |
| Operating Income | 4,203,770 | 1,429,047 | 1,533,008 | 1,375,999 | 3,502,472 |
| Interest Expense | 291,394 | 358,608 | 274,682 | 674,357 | 346,111 |
| Other Income | 25,292 | 454,451 | 163,941 | -982,002 | 218,767 |
| Pre-tax Income | 3,937,668 | 1,524,891 | 1,422,267 | -280,359 | 3,375,128 |
| Income Tax | 810,405 | 321,993 | 178,055 | 332,886 | 612,769 |
| Net Income Continuous | 3,127,262 | 1,202,897 | 1,244,212 | -613,246 | 2,762,359 |
| Minority Interests | 31,888 | 4,308 | 14,114 | -3,299 | 14,149 |
| Net Income | $3,095,374 | $1,198,590 | $1,230,098 | $-609,947 | $2,748,210 |
| EPS Basic Total Ops | 1.24 | 0.48 | 0.49 | -0.25 | 1.10 |
| EPS Basic Continuous Ops | 1.25 | 0.48 | 0.50 | -0.25 | 1.10 |
| EPS Diluted Total Ops | 1.24 | 0.48 | 0.49 | -0.25 | 1.10 |
| EPS Diluted Continuous Ops | 1.25 | 0.48 | 0.50 | -0.25 | 1.10 |
| EPS Diluted Before Non-Recurring Items | 1.57 | 0.93 | 0.96 | 0.89 | 1.39 |
| EBITDA(a) | $4,203,770 | $1,429,047 | $1,533,008 | $1,375,998 | $3,502,472 |